Bio-Path Q3 net loss $2.1M; expands DNAbilize into obesity; cash $0.6M

BIO-PATH HOLDINGS, INC.

2024-Q3 EPS reported -$4.05

Net loss of $2.1M ($0.70 per share) vs $3.2M ($6.36) in Q3 2023; R&D expense down to $1.3M from $2.3M.
Cash of $0.6M as of Sept 30, 2024 (Dec 31, 2023: $1.1M); operating cash burn $7.7M YTD 2024.
Initiated BP1001-A obesity program in October, first non-oncology application of DNAbilize technology targeting Grb2 insulin resistance.
Completed enrollment for third dose cohort of BP1002 Phase 1/1b trial in venetoclax-resistant AML patients ahead of schedule.
Closed $4.0M private placement in October: 4.6M shares and warrants at $0.87 per unit.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.